Drug-resistant tuberculosis

Summary

Drug-resistant tuberculosis (MONDO:0041806) is a disease and 17 clinical trials. Top therapeutic interventions include bedaquiline, delamanid, and moxifloxacin. A subtype of tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	drug-resistant tuberculosis
Mondo ID	MONDO:0041806
SNOMED CT	423709000
UMLS	C0206525
MedGen	61616
GARD	0025841
Is cancer (heuristic)	no

Also known as: drug resistant tuberculosis

Disease family

This is a subtype of tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › drug-resistant tuberculosis

Related subtypes (11): extrapulmonary tuberculosis, pulmonary tuberculosis, endocrine tuberculosis, tuberculoma, latent tuberculosis infection, active tuberculosis, tuberculous encephalopathy, primary tuberculous lymphadenitis, primary bone and joint tuberculosis, multifocal tuberculosis, primary tuberculosis of the digestive system

Subtypes (4): multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, extensively drug-resistant tuberculosis, totally drug-resistant tuberculosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE1	3
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06649721	PHASE3	ACTIVE_NOT_RECRUITING	Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
NCT07268664	PHASE3	NOT_YET_RECRUITING	Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
NCT03338621	PHASE2/PHASE3	COMPLETED	Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
NCT04179500	PHASE2	COMPLETED	A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
NCT06224036	PHASE2	UNKNOWN	Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis
NCT02236078	PHASE1	COMPLETED	Brief Bactericidal Activity of Anti-Tuberculosis Drugs
NCT04493671	PHASE1	COMPLETED	Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
NCT05526911	PHASE1	COMPLETED	A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
NCT05553236	Not specified	RECRUITING	Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
NCT05671718	Not specified	RECRUITING	Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
NCT06590428	Not specified	RECRUITING	Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
NCT02234908	Not specified	COMPLETED	Rewards for Tuberculosis Contact Screening
NCT03266003	Not specified	COMPLETED	An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
NCT04119375	Not specified	COMPLETED	Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes
NCT04147676	Not specified	COMPLETED	Evaluation of Centralised TB Assay Solutions
NCT05017324	Not specified	UNKNOWN	Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
NCT05175794	Not specified	COMPLETED	Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEDAQUILINE	4	3
DELAMANID	4	2
MOXIFLOXACIN	4	2
PRETOMANID	4	2
PYRAZINAMIDE	4	2
CLOFAZIMINE	4	1
LINEZOLID	4	1
TBAJ-876	2	2
CHEMBL4746300	0	2
CHEMBL5285059	0	2